TRINETRA › Sectors › Healthcare
Granules India Limited (GRANULES) — share price, P/E and fundamentals
Granules India Limited (NSE: GRANULES) closed at ₹839.75 on 30 Oct 2026, +47.4% over one year, against a 52-week range of ₹529.85 – ₹923.65.
In the quarter ended 30 Jun 2026 (consolidated, filed 21 Jul 2026) it reported revenue of ₹1,477 cr and net profit of ₹180 cr, a 12.2% net margin; revenue grew 22.0% and profit grew 66.3% year on year.
On four consecutive filed quarters its trailing P/E is 31.4; since 28 May 2025 its own P/E has ranged from 21.2 to 37.0 (median 27.6), and today's reading is higher than 78% of those 352 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 14.2%, ROCE 18.6%, debt-to-equity 0.26, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 46% of 63 sector peers; PBT margin higher than 41% of 63 sector peers; ROE higher than 52% of 63 sector peers.
Key figures
| Last close | ₹839.75 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.6% / +21.8% / +47.4% |
| 52-week low – high | ₹529.85 – ₹923.65 |
| Market capitalisation | ₹20,809 cr |
| Trailing P/E | 31.4 |
| Price / book | 4.09 |
| EV / EBITDA | 16.4 |
| Earnings yield | 3.2% |
| TTM EPS | ₹26.73 |
| TTM net profit | ₹662 cr |
| Quarter revenue | ₹1,477 cr |
| Quarter net profit | ₹180 cr |
| Net margin | 12.2% |
| Revenue growth (YoY) | +22.0% |
| Profit growth (YoY) | +66.3% |
| Return on equity | 14.2% |
| ROCE | 18.6% |
| Debt / equity | 0.26 |
| Current ratio | 1.80 |
| Free cash flow | ₹235 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹53.9 cr |
Against Healthcare peers
| Metric | GRANULES | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.19 | 12.89 | 46 |
| PBT margin | 16.28 | 17.68 | 41 |
| ROE | 14.16 | 13.86 | 52 |
| ROCE | 18.59 | 16.59 | 60 |
| Debt / equity | 0.26 | 0.11 | 68 |
| Cash conversion | 1.33 | 1.25 | 56 |
| Trailing P/E | 31.42 | 43.26 | 22 |
| P/B | 4.09 | 6.02 | 26 |
Questions
What is the P/E ratio of Granules India Limited?
Granules India Limited's trailing P/E is 31.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 21.2–37.0.
What were Granules India Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Granules India Limited reported revenue of ₹1,477 cr and net profit of ₹180 cr (consolidated), filed with the exchange on 21 Jul 2026.
What is Granules India Limited's ROE?
Return on equity is 14.2% based on the balance sheet dated 31 Mar 2026.
Does Granules India Limited have debt?
Debt-to-equity is 0.26 on the balance sheet dated 31 Mar 2026.
What is GRANULES's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, GRANULES traded between ₹529.85 and ₹923.65.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.